Ventiv Scientific's V-PULSE System Succeeds in First Human Trials

Ventiv Scientific has announced the successful completion of its first-in-human clinical cases using the V-PULSE™ Mechanical Thrombectomy System, a novel platform designed to remove blood clots from peripheral vasculature. The system addresses critical conditions such as Deep Vein Thrombosis (DVT), Acute Limb Ischemia (ALI), Critical Limb Ischemia (CLI), Chronic Total Occlusions (CTO), and Pulmonary Embolism (PE). Dr. Makmood Razavi of St. Joseph Heart & Vascular Center noted that the V-PULSE system effectively removed significant clot burden and provided immediate visual confirmation through its integrated filtration technology, offering excellent control and procedural efficiency.

Unlike conventional aspiration systems that rely on continuous vacuum, the V-PULSE system gives physicians real-time control over aspiration force at the catheter tip, allowing rapid adjustments to minimize clogging and reduce blood loss. John O'Connor, President of Ventiv Scientific, emphasized that the platform optimizes aspiration efficiency while remaining compatible with existing hospital pumps. The company's thrombectomy portfolio already includes the FDA-cleared Control Aspire® system for peripheral and coronary applications, and it is developing next-generation technologies like a multi-strut thrombectomy basket retrieval platform.

Ventiv Scientific, a privately held medical device company, focuses on innovative vascular interventions. The V-PULSE system's success marks a significant step in improving procedural outcomes for thrombotic disease. For more details, visit www.ventivscientific.com.